Up, down, now up again! ... what's next IN VIVO Blog faithful? Take a minute to vote before commencing your weekends:
(email subscribers, click here to vote!)
skip to main |
skip to sidebar
Blog Archive
-
▼
2009
(463)
-
▼
March
(51)
- Crash Test: What Pharma Can Learn from Other Indus...
- Saxagliptin: Calendar Management
- Betting on the Saxagliptin Advisory Committee
- Essex Looks to Stretch Many Bucks
- While You Were At ACC
- DotW: On the Verge
- The IN VIVO Blog Podcast: Sandoz's View On US Bios...
- The IN VIVO Blog Poll Results: Bye Bye Avandia
- Following Up With Sid Wolfe (Part 2)
- DNA's Tombstone
- Haddad the Harbinger: Waxman-Hatch Activist Create...
- Why Plan B Still Matters
- Following Up With Sid Wolfe (Part One)
- The IN VIVO Blog Podcast: All M&A Edition
- Fighting Like a Wolfe Against Johnson & Johnson
- There’ll be No Follow-On Biologics in the US at Al...
- While You Were Watching Hoops
- DotW: It's A Mad Mad Mad Mad World
- The Cost of Money
- Seroquel Lessons: Raised Eyebrows and Furrowed Brows
- Harvard's Biederman: After Me, There Is Only God
- If FDA Pulls a Drug, Which One Will It Be?
- The IN VIVO Blog Podcast: All FDA Edition
- FDA Commish To Employees: Keep Quiet or Else!
- Prasugrel Backlash Doesn't Deter Kaul
- While You Were Studying Bracketology
- DotW: The Future of Primary Care?
- Galson’s Next Career Move: Tobacco Chief?
- Health Care Reform and Pharma: Keep Industry "Heal...
- FDA's "Secret" Opioid REMS Meeting
- Yale's Rick Lifton: On the NIH Shortlist
- The IN VIVO Blog Podcast: Lets Make a Deal!
- Smoke Signals Look Good for Biopharma
- Imagining Lunch With Dick Clark
- Merck/SGP: Change of Control and Executive Pay Col...
- Merck and Schering-Plough: Vive La Difference?
- While You Were Mulling It Over
- DotW: Pink Is The New Black
- FDA Commissioner Hamburg
- Roche Raises Genentech Bid to $93/share
- Whoops! Did We--and Novo--Speak Too Soon?
- Health Reform Summit: BIO's Invitiation Lost in th...
- The Horse Race at Bristol
- Out of Africa: US Court Ruling in Trovan Case Affl...
- Novo Confident of Victoza Victory at FDA in May
- Supreme Court Shoots Down Wyeth Pre-Emption Argument
- FDA and Tobacco: Yes, They’re Serious
- Sticker Shock May Open Innovation in Pharma
- The IN VIVO Blog Podcast: Thoughts on Pfizer-Wyeth
- Focus or Diversify? For VCs, Why Not Both?
- While You Were Throwing Snowballs
-
▼
March
(51)
Followers
Total Pageviews